All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
MaaT033 is a fecal microbiota product produced from pooled allogeneic human material. The GvHD Hub has previously reported on MaaT013 for gastrointestinal and steroid-refractory graft-versus-host disease. Previous studies have suggested that use of fecal microbiota therapy could improve outcomes, such as overall survival after an allogeneic hematopoietic stem cell transplant.1
At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Florent Malard presented the planned study design and methods of the phase II PHOEBUS trial (NCT05762211) of MaaT013 in patients ≥50 years with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplant.
Figure 1 outlines the key inclusion criteria of the PHOEBUS trial.
Figure 1. Key inclusion criteria
Figure 2. Key facts about the PHOEBUS trial*
*Data from Malard.1 Created with BioRender.com
This trial is still ongoing and the first results are expected later in 2024.
MaaT013, a pooled microbiota therapy, for the treatment of GI-aGvHD
At the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, Mohamed Mohty discussed the early-access program of MaaT013, a pooled microbiota therapy, in patients...
Update from the Heracles trial and expanded access program of MaaT013 in patients with SR aGvHD
During the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 47th Annual Meeting of the European Society for Blood and Marrow...
Is the microbiota biotherapeutic MaaT013 a safe and effective option for steroid-refractory GI GvHD?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Florent Malard, Hôpital Saint-Antoine,...
Subscribe to get the best content related to GvHD delivered to your inbox